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Abstract
Background: Cardiovascular toxicity is a major limiting factor in drug development and requires multiple cost-
effective models to perform toxicological evaluation. Zebrafish is an excellent model for many developmental,
toxicological and regenerative studies. Using approaches like morpholino knockdown and electrocardiogram,
researchers have demonstrated physiological and functional similarities between zebrafish heart and human heart.
The close resemblance of the genetic cascade governing heart development in zebrafish to that of humans has
propelled the zebrafish system as a cost-effective model to conduct various genetic and pharmacological screens
on developing embryos and larvae. The current report describes a methodology for rapid isolation of adult
zebrafish heart, maintenance ex vivo, and a setup to perform quick small molecule throughput screening, including
an in-house implemented analysis script.
Results: Adult zebrafish were anesthetized and after rapid decapitation the hearts were isolated. The short time
required for isolation of hearts allows dissection of multiple fishes, thereby obtaining a large sample size. The
simple protocol for ex vivo culture allowed maintaining the beating heart for several days. The in-house developed
script and spectral analyses allowed the readouts to be presented either in time domain or in frequency domain.
Taken together, the current report offers an efficient platform for performing cardiac drug testing and
pharmacological screens.
Conclusion: The new methodology presents a fast, cost-effective, sensitive and reliable method for performing
small molecule screening. The variety of readouts that can be obtained along with the in-house developed
analyses script offers a powerful setup for performing cardiac toxicity evaluation by researchers from both
academics and industry.
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Background
The drug discovery process is heavily impeded by cardio-
vascular toxicity [1]. The sooner toxicity is discovered, the
better for preclinical safety standards and cost of drug
development. Various in vitro assays such as membrane
potential dyes [2], rubidium efflux [3], radioligand binding
[4] and patch clamp [5] have been used to identify com-
pounds displaying cardiac toxicity. Since a compound can
affect more than one target, it is necessary to understand
the effects on the whole organ system. Therefore, various
ex vivo assays such as the purkinje fiber assay [6], isolated
heart assay [7] and in vivo assay using transgenic mice [8]
have emerged. However, these assays are limited in specifi-
city, reliability and throughput efficiency. Thus, more
model systems are needed to evaluate cardiovascular
toxicity.
Zebrafish has gained immense popularity as a model for
small molecule screening for factors influencing the cardi-
ovascular system [9-11]. Various screens have been per-
formed on zebrafish embryos and larvae to study factors
influencing development and homeostasis of the cardio-
vascular system [11]. The availability of transgenic zebra-
fish lines expressing fluorescent proteins in the vascular
s y s t e m ,b l o o d ,e n d o t h e l i a lcells and heart, facilitates
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pounds on the cardiovascular system [12]. The small size,
relative ease in handling, and the possibility of obtaining a
large number of samples (embryos or adult fish) for statis-
tical evaluation, offers a reliable platform for performing
small molecule screening.
The current report describes a method for rapid isola-
tion of intact adult zebrafish hearts, maintenance ex vivo
and presents a platform for small molecule screening on
multiple hearts. This setup offers a reasonable through-
put-screening platform for generating rapid and statisti-
cally significant readouts. Readouts can range from
recording heartbeats or temporal changes in morphology
to measuring cellular calcium (Ca
2+) signaling, rhythmic
beating and force of contraction. Taken together, this ex
vivo cardiac assay model offers a powerful tool for evaluat-
ing several dimensions of potential cardiovascular toxicity
of lead compounds.
Methods
Preparation of reagents
Adult wild type AB strain zebrafish to be dissected were
transferred to Egg Water containing “Instant Ocean” sea
salts to a final concentration of 60 mg/ml, and anesthetic
solution containing 0.1% Tricaine (Sigma) in Egg Water
was prepared as described in The Zebrafish Book (Univer-
sity of Oregon Press, 2000). Krebs-Ringer’ss o l u t i o n
(onward referred to as Krebs solution) for dissection and
screening was prepared by mixing NaCl (119.0 mM), KCl
(2.5 mM), NaH2PO4 (1.0 mM), CaCl2:2 H 2O( 2 . 5m M ) ,
MgCl2:6 H 2O (1.3 mM), HEPES (20 mM) and D-glucose
(11.0 mM). The solution was adjusted to pH 7.4 and filter
sterilized using a 0.2 μm filter (Sarstedt). If Ca
2+ responses
were to be recorded, Fura-2/AM (Molecular Probes) was
used at a final concentration of 0.2 mM in Krebs solution.
Culture medium for maintaining the hearts was prepared
by adding fetal bovine serum (Invitrogen) to a final con-
centration of 10% in DMEM (Invitrogen). The 0.5 to 1%
low-melt agarose solution was prepared in filtered Krebs
solution.
Animal husbandry and rapid dissection of the adult
zebrafish heart
Adult zebrafish of 4-6 months were anesthetized and
immediately transferred to a Petri dish under a microscope
for dissection. Using two forceps (Dumont Forcep No 5,
Sigma), the zebrafish was rapidly decapitated. One forceps
was used to hold the body of the zebrafish and the other
forceps was then inserted into the body cavity below the
pectoral fin and the overlying skin was pulled away to
reveal the beating heart. The heart was carefully pulled
away from the rest of the body and all other tissues were
cleared from the Petri dish (Figure 1A).
Ex-vivo culture
The hearts were transferred to a 12 well plate, each well
having 1 ml of culture medium, and incubated at 37°C.
We have successfully maintained beating hearts for up
to 4 days without any contamination. Maintaining the
hearts at temperature optimal for fish (28.3°C) can also
be done without major impact on its survival and per-
formance. For evaluating this assay, organotypic culture
of adult mice heart and in vitro culture of immortalized
HL-1 cardiomyocytes were done using previously
described protocols [13,14]
Setup for performing small molecule screening
The screening procedure can be performed with 3-5
heart preparations, either embedded or un-embedded in
agarose, in a glass bottom Petri dish (MatTek). First, the
glass bottom of the dish was coated with laminin
(Sigma), diluted 1:200 with Phosphate Buffered Saline
(Invitrogen) from the stock concentration of 1 mg/ml
and incubated for at least 3 h at 37°C. Excess laminin
solution was removed and 3-5 hearts were transferred
to the Petri dish with as little culture medium as possi-
ble. If Ca
2+ measurements were to be performed, the
hearts were incubated for 10 min at 37°C with 5% CO2,
immersed in 100 μl of 0.5 mM of Fura-2/AM. Next,
150 μl of Krebs solution was added to the Petri dish and
incubated for an additional 30 min. After transfer of the
heart to the Petri dish, excess culture medium or Fura-
2/AM was removed and 1-2 drops of low melt agarose
(Lonza) was pipetted onto the heart (Figure 1B). The
agarose was allowed to solidify and 1 ml of pre-warmed
Krebs solution was added into the Petri dish. The same
setup was also used for performing comparative screens
on mouse heart and HL-1 cell cultures.
Performing screening on zebrafish heart
The Petri dish with embedded hearts was moved to the
screening station (Figure 1C) and mounted on a tempera-
ture-controlled stage setup (Warner Instruments)
clamped onto a Zeiss Axiovert 100 M microscope,
equipped with a 25X/0.8NA water immersion objective
and a 5x/0.15NA objective (all from Carl Zeiss), con-
nected to a Lambda LS xenon-arc lamp, Lambda 10-3 fil-
ter-wheel and a smartShutter (all from Sutter
Instruments). A container was filled with freshly pre-
pared and pre-warmed Krebs solution for washing the
samples in between compound treatments. A peristaltic
pump was used to add and remove the washing buffer to
hearts in the mounted Petri dish. Recording of heartbeats
(Figure 1D) or spontaneous Ca
2+ signals (Figure 1E-F)
were acquired at 5 and 0.5 Hz respectively with an
EMCCD camera Cascade II:512 (Photometrics) con-
trolled by the acquisition software MetaFluor (Molecular
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screening. Compounds were then added directly to the
Petri dish using a pipette and changes in heart beating or
Ca
2+ signaling were captured. Following this procedure,
the compound was rinsed off by allowing Krebs solution
to flush the hearts. Thereafter, the recording continued
until a signal was detected that resembled the initial con-
trol reading whereupon a second compound was added
(Figure 2A). This process could be repeated as long as a
stable control reading could be detected after each
treatment.
Quick analyses of the heartbeats
Bright field time-lapse movies of beating hearts were
imported to ImageJ and regions of interest (ROI) encom-
passing the border of the hearts were marked. The mean
intensities of each time point in the time-lapse recording
were extracted, using the MultiMeasure plugin, and
saved in a .dat file. The values within this file were
thereafter imported to an in-house MATLAB software
tool beating.m (Additional file 1: Table S1) or into a pre-
viously described spectral analysis software tool, also
implemented in MATLAB, to characterize the temporal
properties of heart beating [15]. These algorithms nor-
malize the time-series and remove any possible trend-
lines, produced by e.g. focus shift, by fitting the trace to a
polynomial (Figure 1D).
Single or multiple heart preparations were used for cap-
turing dynamics of Ca
2+ signaling (Figure 1E). For analyz-
ing Ca
2+ signals, the MetaFluor software was used to
extract the Fura-2/AM intensities in different ROIs. The
data was then exported to Excel and a graph was plotted
(Figure 1F).
Results and discussion
In order to set up the screening platform for dissected
hearts, real-time recordings of heart beating (Figure 1D)
and Ca
2+ fluxes (Figure 1E-F) were performed and
Figure 1 A) Whole heart, isolated from wild type adult zebrafish showing Atrium (abbreviated: at) and Ventricle (abbreviated: v).B )
Petri dish with embedded hearts used for screening. C) Diagrammatical representation of the screening setup. Petri dish with embedded hearts
is placed on an inverted microscope having an in- and out-let to regulate the in- and out-flow of fresh Krebs buffer. D) Analyses of heartbeating
using MATLAB. E) Three hearts mounted on a Petri dish to measure Ca
2+ responses. The regions of interest (ROI1 and ROI2) that were used to
analyze Ca
2+ responses are shown with blue and red circles. F) Graph showing spontaneous Ca
2+ activity and compound-induced Ca
2+ response
in ROI1 (in blue) and ROI2 (in red). Analyses of heartbeats at 28°C G) and 37°C H). Analyses of heartbeats obtained from screen of compounds as
indicated carried out at 28°C I) and 37°C J). Compound concentrations of 10 μM were used in the screen. Scale bar: 200 μmi nA .
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mented in MATLAB (Additional file 1: Table S1). Both
heartbeats and Ca
2+ recordings displayed steady periodi-
city with little fluctuations over time. As the heartbeat
recordings were more robust and easy to conduct, this
readout was used in further screens. To validate the
screening platform, the beating of the heart was moni-
tored at both 28°C and 37°C (Figure 1G-H), following
application of three hERG channel modulators, using a
screening flowchart (Figure 2A). The beating and response
to compounds were more significant at 37°C than at 28°C
(Figure 1I-J). In drug development, human hERG potas-
sium channels are of utmost importance as they are cru-
cial for cardiac action potential repolarization. Inhibition
or reduced function of hERG channels delay ventricular
action potentials causing cardiac arrhythmia which can
result in cardiac arrest. Hence, it is of utmost importance
that hERG related effects of novel compounds are identi-
fied at early stage of drug development. Similar to hERG-
induced cardiac arrhythmia in humans, a clear impact on
t h ea m p l i t u d ea n df r e q u e n c yo fb e a t i n gw a ss e e nw h e n
compounds were administered to the zebrafish heart. This
indicated that screening could be reliably performed at 37°
C, using both acute and chronic assessments to carry out
real-time recordings to provide additional mechanistic
insights into the effect of compounds on cardiac activity.
Our data also indicates that this model offers a good plat-
form to test hERG-related effects of compounds.
To evaluate beating irregularities, spectral analysis was
utilized on the time-series from beating hearts. The Four-
ier transform converts the signal in time-domain to its
correspondence in frequency domain. The peaks in the
spectra represent different frequencies of sine wave com-
ponents of the original oscillatory signal. Compounds pro-
ducing spectra identical to untreated hearts were
considered to have no cardiac effect. Dramatic changes in
heart beating (as seen in Additional file 2: Movie S2 show-
ing the effect by Clofilium when compared to no effect of
Figure 2 A) Flowchart showing the screening procedure to assess compounds. B-I) Spectral analyses of heartbeats from hearts treated with
various compounds. Spectra from control (DMSO) treatments or untreated hearts are shown in blue, while spectra from compound exposures
are shown in red. B-C) Spectra from hearts treated with two different concentrations, as indicated, of clofilium. Spectra from hearts treated with
different Ca
2+ channel modulators D-E), chloride transport inhibitors F-H) and blebbistatin I). Compound concentrations of 10 μM were used in
the screen. Data shown in panels B-D, E-G and H-L were generated by three separate screening.
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spectra were clearly observed with clofilium (Figure 2B), a
potent hERG channel inhibitor. Clofilium at concentra-
tions below 5 μM produced spectra similar to untreated
hearts, indicating lack of readable effects (Figure 2C-D).
As expected, modulators of Ca
2+ signaling were producing
striking shifts in the spectra (Figure 2E-F). Compounds
modulating potassium channels (Figure 2B-D) and inhibi-
tors of chloride channels had less effects (Figure 2H-J).
The inhibitor of myosin heavy chain ATPase activity, bleb-
bistatin, had a dramatic effect on the spectrum (Figure
2K). Galantamine, a previously used Alzheimer’s disease
drug, with no documented cardiac effects, was without
effect on the spectrum (data not shown), indicating no
cardiac toxicity. Taken together, these results demon-
strated that this setup offers a reliable platform for drug
screening.
Similar experiments on organotypic cultures of mouse
heart sections and on cultured cardiomyocytes were car-
ried out for comparison. Exposure of cardiomyocytes to
clofilium or blebbistatin yielded similar spectrums as pro-
duced by the zebrafish heart (Figure 3A-C). When clofi-
lium was applied, the beating of the mouse heart ceased
(data not shown). Our data shows that this assay can sen-
sitively and precisely detect a range of effects that comple-
ment existing models. Thus, this assay has the potential to
be used as a major screening model system for cardiac
toxicity assessment or can be integrated as a part of multi-
model cardiac toxicity risk assessment.
Small molecule screening of compounds affecting car-
diovascular performance in zebrafish embryo or larvae
has been immensely successful thereby reflecting on the
robustness of this model as a reliable screening platform.
Accumulating data indicate a very high degree of devel-
opmental and functional similarity between zebrafish and
human heart, facilitating evaluation of cardiac-toxicity in
terms of human health risks. This platform allows usage
of multiple hearts for testing/screening with generation
of statistically significant data and little sample variation.
The isolated hearts can be maintained in culture ex vivo
and screening can be performed with multiple candidate
molecules, with alternating washing steps. The time
required for assessment of one compound is around 3-5
min, allowing scalability and automation. The number of
compounds that can be used in one screen depends on
whether a stable baseline recording is established after
the compound is washed away. The possibility of main-
taining beating hearts ex vivo allows recording of acute
and chronic effects on the cardiac function and viability.
Short-term or long-term readouts like heartbeat,
mechanical contraction, viability, hERG activity, or Ca
2+
Figure 3 Spectral analyses of the beating efficiency of
immortalized HL-1 cardiomyocytes after exposure to DMSO
(A), clofilium (B) and blebbistatin (C). Compound concentrations
of 1 μM were used in the screen.
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offering a sensitive model to assess cardiac toxicity.
Screening with zebrafish heart maintained ex-vivo for
four days yield similar results as screening on freshly iso-
lated heart (data not shown), however, the number of
compounds that can be tested with a single heart mark-
edly decreased (data not shown). Compounds primarily
affecting the contractility properties of the heart (eg.
Blebbistatin) may be missed by electrophysiological
methods, but can be evaluated here. Although this model
requires extensive validation, it clearly demonstrates fea-
tures such as sensitivity to generated readouts, reliability
and adaptability with other available methods (such as in
vitro cardiomyocyte screens). The Matlab script and the
spectral analyses allow display of the readout in time
domain or in frequency domain respectively, thereby pro-
viding deeper understanding of the effects produced by
the compounds.
Cardiac safety evaluation is an important part of the
drug discovery and development process; hence a whole
organ assay model would be highly beneficial. Numerous
drug candidates are regularly evaluated using multiple
cell lines based assays. Although the adult heart-screen-
ing assay requires higher concentrations of test com-
pounds than cell lines or zebrafish embryos/larvae, this
assay offers a possibility to test various aspects on whole
organ from an adult fish. Since diverse cell types contri-
bute to the function of the entire adult heart, this assay
allows precise measurements of the effects produced on
all type of cells, governing the function of the organ. Res-
cue screens performed on hearts isolated from adult
mutant zebrafish with heart defects (eg. Slow mo) will be
highly beneficial for studies on heart development, regen-
eration and homeostasis using chemical genetics, as well
as aiding in the process of drug discovery.
Conclusion
Features such as rapid dissection and maintaining the
heart ex vivo for several days offers an excellent possibi-
lity for carrying out time series recording or acute and
chronic studies in addition to compound screens. The
small size and relatively cheap housing of the fish pro-
vides a cost effective setup in comparison to other in
vivo or ex vivo models. The hearts can be easily pro-
cessed for immunohistochemistry or in situ hybridiza-
tion with standard protocols thereby enabling testing of
the expression of various biomarkers before and after
exposure to the test compounds. Experiments aiming at
determining the structure activity relationship (SAR) or
reverse medicinal chemistry approach to classify the
effect of various structurally diverse compounds on the
heartbeat or the spectral profile it generates can be
easily adapted to this model. In conclusion the current
report clearly demonstrates a platform for performing
cardiac toxicity evaluation either as a primary screen or
as complement to existing methodologies.
Additional material
Additional file 1: Table S1. MATLAB script for analyzing heartbeats.
Additional file 2: Movie S2. Movie of beating zebrafish heart after
addition of Krebs buffer containing clofilium to a final concentration of
10 μM.
Additional file 3: Movie S3. Representative movie showing beating of
zebrafish heart in Krebs buffer and after addition of DMSO control.
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